Tamoxifen prevention of breast cancer: An instance of the fingerpost

Journal of the National Cancer Institute

Volumn 91, Issue 21, 1999, Pages 1809-1819

  Lippman, S M ^a   Brown, P H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; BEXAROTENE; DROLOXIFENE; ESTROGEN RECEPTOR; IDOXIFENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; RALOXIFENE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TAMOXIFEN; TOREMIFENE; TRANSCRIPTION FACTOR AP 1;

BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG MECHANISM; DRUG SELECTIVITY; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; FEMALE; FRACTURE; HORMONE RESPONSIVE ELEMENT; HOT FLUSH; HUMAN; LUNG EMBOLISM; NONHUMAN; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; VAGINA DISCHARGE;

EID: 0033520706     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.21.1809     Document Type: Note

References (104)